Clinical Trial

A Real-world Study of Characteristics, Treatment Patterns, and Clinical Outcomes Among Lutetium-177 Vipivotide Tetraxetan Treated Patients

Completed
View on ClinicalTrials.gov →
Summary
The aim of this study was to assess the characteristics, treatment patterns, and clinical outcomes among metastatic castration-resistant prostate cancer (mCRPC) patients in the United States (US) who were treated with lutetium-177 vipivotide tetraxetan (177Lu-PSMA-617) in the real-world setting.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-03-12.
Trial Details
NCT Number NCT07477756
Lead Sponsor Novartis Pharmaceuticals
Conditions Prostate Cancer
Enrollment 1,247 participants
Start Date 2024-09-04
Primary Completion 2025-03-14 (estimated)
Study Completion 2025-03-14 (estimated)
Updated on ClinicalTrials.gov 2026-03-19